Under the Paperwork Reduction Act of 1995, no persons are required

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)
(Not for Submission under or of it may

Application Number		
Filing Date		2006-08-11
First Named Inventor	Rong	ZHENG
Art Unit		
Examiner Name		
Attorney Docket Number	er .	ARC-2

		· ·			U.S.I	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue E	Date	Name of Patentee or Applicant		Releva		ines where es or Relev	
	1	6492050	B1	2002-1	2-10	Acumentrics Corporation					
If you wisl	h to a	ı dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.	_	Add		_
			U.S.P	ATENT	APPLIC	CATION PUBL	LICATIONS		Remove		_
Examiner Initial*	Cite No	Publication Number	on Number Kind Publication Name of Patentee or Applicant Relev				Releva		ines where		
	1										
If you wisl	h to a	dd additional U.S. Publi		p		, , , , , , , , , , , , , , , , , , , ,		d button	$\overline{}$		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code4	Publication Date	Applicant of cited		where Rele	or Relevant	+
	1										_
If you wisl	h to ac	dd additional Foreign P	atent Do	cument	citation	information pl	ease click the Add	button	Add		_
			NON	-PATE	NT LITE	RATURE DO	CUMENTS	_	Remove		_
Examiner Initials*	Cite No	Include name of the ar (book, magazine, journ publisher, city and/or of	nal, seria	al, symp	osium,	catalog, etc), o					Тs

	Application Number		
NEODMATION DIOCE COURT	Filing Date		2006-08-11
NFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Rong	ZHENG
Not for submission under 37 CFR 1.99)	Art Unit		
Not for Submission under or or it issue	Examiner Name		
	Attorney Docket Numb	er	ARC-2

	1			
If you wis	h to a	Id additional non-patent literature document citation information please click the Add button	Add	_

EXAMINER SIGNATURE

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Code of USPTO Patent Documents at inverUSPTO_GOLY or MPEP 901.94. 2 Enter office that issued the document, by the involved own (WIPO Standard ST3.). *Produces persist or counters, the oricidation of the year of the region of the Emperor many precedure the settle undervised the patent document. **

**Varied of counterity this appropriate symbols as endicated on the document under WIPO Standard ST1.64 (possole, *2 Applicant is to place a check mark here it region is language treated ions is data-order.)

Application Number Filing Date 2006-08-11 Filing Date 12006-08-11 Filing Date 2006-08-11 First Number Number Rong 27/ENG Art Unit Examiner Name Attorner Oochet Number ARC-2

CERTIFICATION STATEMENT

Please see	37.0	CFR 1	97	and :	1 98	to make	the	appropriate	selection(s)	

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(eVI).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, to father of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/97(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Brian L. Johnson/	Date (YYYY-MM-DD)	2006-08-11
Name/Print	Brian L. Johnson	Registration Number	40033

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 37 CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.231.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.